Media Center

Introduction Recombinant protein production is essential for pharmaceutical development, diagnostics, and industrial applications. However, achieving high yields of soluble, active proteins – especially for difficult-to-express targets – remains a significant challenge. This article explores advanced solutions for cost-effective protein production, from overcoming expression limitations in standard E. coli strains to implementing extracellular secretion strategies that simpli

Discover the ground-breaking ECOnti project, where enGenes Biotech and partners have developed an integrated continuous manufacturing process that’s transforming biotechnology production. See how multiple industry partners have come together to create a seamless, continuous manufacturing system that enhances efficiency, reduces costs, and advances the future of biotechnology manufacturing. To watch the video, clink on this link: https://www.pharmaceutical-networking.com/econt

Vienna, Austria: – enGenes Biotech GmbH (enGenes) will share details of its progress towards the world’s first platform for truly continuous production of plasmid DNA (pDNA) with the bioscience community at the 44 th International Symposium on the Separation of Proteins, Peptides and Polynucleotides (ISPPP) in Munich. As part of the  Continuous and Intensified Processing  session, enGenes Senior Bioprocess Scientist Dr. Markus Berg will present  “Continuous Downstream Process

Vienna, Austria: – enGenes Biotech GmbH (enGenes) will show its highly advanced bioprocessing solutions in protein expression and vaccine development at Europe’s flagship life sciences partnering conference, BIO-Europe 2025, this year in Vienna. The enGenes team will join other hi-tech biotech companies as part of a combined national presence at the Austrian Pavilion operated by LISAvienna, located at C32 GL in Hall C of the Messe Wien expo center. Enhanced yield expression T

When nucleic acid contamination in protein purification isn’t controlled, you face sticky lysates, slower chromatography, and reduced protein yield. Residual DNA also risks regulatory non-compliance. Learn how using endonucleases effectively can streamline processes, reduce unit economics, and make nuclease treatment a practical solution from early development to large-scale manufacturing. From uncovering how proteins work at the bench to developing therapeutic biologics or s

Vienna, Austria: – Bioprocessing solutions expert enGenes Biotech will share insights into its advanced vaccine development capabilities...

Vienna, Austria: – Bioprocessing solutions expert enGenes Biotech is ready to unveil the first working prototype of a fully automated and...

Vienna, Austria: – Bioprocessing solutions expert enGenes Biotech has been invited to make its first-ever appearance at the Bioprocessing...

Vienna, Austria: – Five months after attending the European BioProcess Summit in Barcelona, recombinant proteins and plasmid DNA...

Recombinant proteins and genetics specialist CDMO enGenes Biotech has embarked on a potentially transformational project to create a...